



NAVIGATE here

Search

GO

- » [Next article](#)
- » [Previous article](#)
- » [Table of Contents](#)

Cat Rental Power Solution Diesel & Natural Gas Generators 24/7 Support For Event Or Emergency [www.catelectricpowerinfo.com/r](#)
Fight Disease with pH Establish and Maintain Healthy pH Balance. The KEY to a healthy life. [Balance7.com](#)
Industrial remote control Radio controls for various machinery and lifting equipment. [www.hbc-radiomatic.com](#)

AdChoices

RESOURCE links

- » [Similar in PUBMED](#)
- » [Search Pubmed for](#)
 - [Subasinghe D](#)
 - [Samarasekera DN](#)

ORIGINAL ARTICLE

Year : 2010 | Volume : 47 | Issue : 2 | Page : 151-155

» Search in Google Scholar for

Delay in the diagnosis of esophageal carcinoma: Experience of a single unit from a developing country

[D Subasinghe](#), [DN Samarasekera](#)

University Surgical Unit, The National Hospital of Sri Lanka, Colombo, Sri Lanka

- [Subasinghe D](#)
- [Samarasekera DN](#)

» Related articles

Date of Web Publication 5-May-2010

- [Delay in diagnosis](#)
- [endoscopy](#)
- [esophageal carcinoma](#)

Correspondence Address:

D N Samarasekera
 University Surgical Unit, The National Hospital of Sri Lanka, Colombo
 Sri Lanka

Login to access the email ID

- » [Article in PDF](#) (492 KB)
- » [Citation Manager](#)
- » [Access Statistics](#)
- » [Reader Comments](#)
- » [Email Alert](#) *
- » [Add to My List](#) *

DOI: 10.4103/0019-509X.63009

PMID: 20448378



* Registration required (free)

» Abstract

In this article

- » [Abstract](#)
- » [Introduction](#)
- » [Materials and Me...](#)
- » [Results](#)
- » [Discussion](#)
- » [References](#)
- » [Article Figures](#)
- » [Article Tables](#)

Objectives : Main objective was to analyze the time delay between the onset of symptoms and the histological diagnosis of esophageal cancer. The subsidiary objective was to analyze the relationship between the time delay and stage of the disease at the time of definitive treatment. **Study Design , Setting , and Methods :** A prospective analysis of patients with esophageal cancer presenting to a single unit over a period of 24 months was performed. Interval from the onset of symptoms to the histological diagnosis and stage at presentation was analyzed. **Results :** There were 48 patients (male = 26) with a median age of 59.5 (range 43 - 84) years. First symptom was progressive dysphagia in all patients. Subsidiary symptoms were, weight loss in 83.3% (n = 40), abdominal / chest pain in 10 (20.8%), regurgitation in 14 (29.2%), odynophagia in three (6.2%), abdominal discomfort in two (3%), and dyspepsia in two (3%). The mean delay from the appearance of the first symptoms to the end point was 14.9 weeks (range 3 - 37 weeks). Total delay was due to patient delay in 82%, endoscopy delay in 7%, and delay in histological diagnosis in 11%. **Conclusions :** As the majority (82%) in our study showed patient delay, a community education program may help in their early presentation to the hospital. However, there is also a notable delay in endoscopy and histology (15%) services, mainly due to a shortage of endoscopy units and qualified histopathologists in the state sector.

Article Access Statistics

Viewed	988
Printed	35
Emailed	1
PDF Downloaded	78
Comments	[Add]
Cited by others	1

Keywords: Delay in diagnosis, endoscopy, esophageal carcinoma

Total downloads in last 2 months

Feb 2012	17
Jan 2012	31

How to cite this article:

Subasinghe D, Samarasekera DN. Delay in the diagnosis of esophageal carcinoma: Experience of a single unit from a developing country. Indian J Cancer 2010;47:151-5

How to cite this URL:


Subasinghe D, Samarasekera DN. Delay in the diagnosis of esophageal carcinoma: Experience from a developing country. Indian J Cancer [serial online] 2010 [cited 2012 Feb 18];47:151-

Impact Factor® for 2011
 0.961 (Projected)
 Thomson Reuters

Ads by Google

[Kids Games](#)

[Download Games](#)



Register with us

- > Get PDF of articles
- > Get e-mail alerts
- > Receive notification of events
- > Add comments on articles
- > Add meetings/events

Click on image for details.

Google Translate

Select Language

Gadgets powered by Google

AdChoices

Bio Sample

Management

Biobank Repositories
Freezer Management
www.labware.com

Biomarker Assay
Specimens

Bring your protocol to our patients Quality Specimens = Better Research
www.promeddx.com

Buy Protocol Online

Order Protocol 23 & Protocol 50. Fast Shipping, Authorized Seller.
www.webnd.com

Getman Mining
Equipment

Underground miners everywhere rely on Getman diesel equipment.
www.Getman.com

Nodule localizer
needles

Italian manufacturer biopsy needles search distributors worldwide
www.mdlsrl.com

from: <http://www.indianjancer.com/text.asp?2010/47/2/151/63009>

» Introduction

Esophageal cancer is the eighth common malignancy worldwide and the third among gastrointestinal malignancies. [1]. [2] It is the fourth common malignancy in the developing world, and recently, some of the Asian countries have also reported a rise in its incidence. [3]

It was responsible for 462 000 new cases (4.2% of the total) and 386 000 deaths (5.7% of the total) in 2002, [4] and it is the sixth leading cause of death from cancer worldwide. [5] It is also one of the most virulent tumors with poor prognosis and not more than 14% of the patients could survive longer than five years despite the recent advances in surgical techniques. [6]. [7] The prognosis for patients with esophageal cancer is closely related to the stage of the disease at the time of diagnosis. The outcome of this cancer is closely related to the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system. [8] According to that, five-year survival rates for Stages I, II, III are 50-80%, 30-40%, and 10-15%, respectively. Stage IV disease treated with palliative therapy has a median survival of < 1 year. [9] Therefore, if the disease is diagnosed and treated early (stages I and II) the outcome may be considerably better than if diagnosed in the late stages (stages III and IV).

According to what the previous studies suggest, where the tumor growth is calculated based on mathematical models, it takes a considerable time period (> 10 years) from the appearance of the first cancer cell to the possibility of detecting a tumor by conventional investigations. [10]. [11] On these grounds someone may suggest that once an esophageal cancer clinically manifests, there has been a long tumor history of a number of years, and therefore, it is unlikely that the prognosis is changed by the relative short delay time in diagnosis and treatment. However, it is important note that the median values of potential doubling time in esophageal tumors is 4 - 5 days with a range of 2 - 20 days among the fastest of all types of tumors. [10] Therefore, a few months of delay may allow the tumor to double several times. Hence, long delays are probably a negative factor for the patient's prognosis. [11] In Sri Lanka, we do not have a screening program to identify the early stages of esophageal cancer. In our experience, a majority of patients present with advanced disease leading to a poor outcome. Therefore a fast diagnostic workup after the first consultation is important, because, a diagnostic delay may lead to delay in treatment. This factor may therefore have an influence on the stage of the esophageal carcinoma and subsequently on the prognosis. Therefore, a fast diagnostic workup is important to detect the disease at an early stage and to improve the outcome, by offering the necessary treatment modalities. At present there are no published data regarding the delayed presentation of esophageal cancer and a possible association between symptom-to-treatment delay or the stage of the esophageal cancer at the time of treatment. Therefore, we performed this study to, identify the time of delay from the first symptom-to-treatment of esophageal cancer investigate the possible correlation between symptom-to-treatment delay and the stage of tumor at the time of presentation

» Materials and Methods

Forty-eight consecutive patients diagnosed as having oesophageal cancer at the National Hospital of Sri Lanka were studied. The patients with cancer arising from the gastroesophageal junction and other esophageal tumors such as leiomyosarcoma were excluded from the analysis. One of the authors interviewed each patient at their first visit to the hospital. Data were collected using a structured data sheet. Data were analyzed using SPSS statistical package version 16.0.

The delay in diagnosis and treatment was measured from the date when the patient first experienced the symptom/s that led to diagnosis. The end point was taken as the date when the patient had definitive histological diagnosis following upper GI endoscopy (UGIE). The overall delay in months was recorded from the appearance of the first symptom/s to the end point, for each patient, and was divided into three periods:

- time from appearance of the first symptoms to first contacting the healthcare system, that is, patient delay
- time from first contacting the healthcare system to endoscopic delay in the diagnosis, that is, endoscopic delay
- histology report delay, that is, histology delay

Endoscopic lesions were classified according to their location, that is, upper, middle, or lower

Impact Factor® for 2011
0.961 (Projected)
Thomson Reuters

esophagus. [\[12\]](#) Upper-third lesions extended from the cricopharyngeal sphincter (15 cm) to the tracheal bifurcation (23 cm). Middle-third lesions extended from 23 cm to 32 cm. Lower-third lesions extended from 32 cm to the gastroesophageal junction (40 cm). If the lesion involved more than one site, both locations were recorded. The American Joint Committee on Cancer (AJCC) staging system was used. Tumor infiltration was staged by Computer Tomography (CT) and /or Endoscopic Ultrasound (EUS).

» Results

Forty-eight patients (26 men and 22 women) were included in this study. The median age when they first developed symptoms was 59.5 (range 43 - 84) years. The first symptom was progressive dysphagia in all the patients (100%). In addition, 40 patients (83.3%) had loss of weight at presentation to the endoscopic examination. Apart from dysphagia, other presenting symptoms were, abdominal or chest pain in 10 (20.8%), regurgitation in 14 (29.2%), odynophagia in three (6.2%), abdominal discomfort in two (3%), and dyspepsia in two (3%) patients, respectively. All patients complained of progressive dysphagia and 46 (95.8%) experienced more than one symptom.

All patients underwent UGIE, barium swallow and staging investigations (i.e., chest X-ray film, abdominal ultrasonography, computed tomography, and/or endoscopic ultrasound).

Tumor location/histology

The tumor was located in the upper (cervical) esophagus in one patient, middle esophagus in 18 (37.5%) patients, and lower esophagus in 24 (50%) patients. In five patients the tumor was seen in both the middle and lower esophagus. Morphology of the tumor during UGIE was, ulcerative, obliterative, proliferative, and ulceroproliferative in 22 (45.8%), 18 (37.5%), 4 (8%), and 4 (8%) patients, respectively. Thirty-four (70.8%) patients had squamous cell carcinoma and 14 (29.2%) had adenocarcinoma. The histopathological differentiations of squamous cell carcinoma were well-differentiated carcinoma in six patients, moderate in 16 patients, and poor in 13 patients. The differentiations of adenocarcinoma were poor in eight patients and moderate in six patients [\[Table 1\]](#). Two (4.1%) patients had stage I disease, eight (16.7%) had stage II disease, 24 (50%) had stage III disease, and 14 (29.2%) had stage IV disease.

According to the preoperative CT scan, 1, 20, 9 and 16 patients had stage I, II, III, and IV tumors, respectively. Two tumors (4.2%) were not detected by CT due to early disease (but confirmed on upper GI endoscopy and histology as moderately differentiated squamous cell carcinoma).

The symptom-to-treatment delay and its impact on the stage of the disease

The median delay concerning the interval from the appearance of the first symptom to the end point was 14.9 weeks. Twenty-seven (56.25%) patients had a delay of three months or more, 19 (39.58%) had four months or more, and six (12.5%) patients had a delay of six months or more [\[Figure 1\]](#) prior to presentation to the hospital.

Delay from the appearance of the first symptom to first contacting the healthcare system accounted for 82.2% of the total, endoscopy delay accounted for 7.1%, and the delay in the histological diagnosis accounted for 10.7%. Forty (83.3%) patients had a delay of more than one month from the appearance of the first symptom to contacting the healthcare system, 25 (52%) patients had more than a two-month delay, and seven (14.6%) patients more than four months. Only seven (14.6%) patients underwent primary esophagectomy and the majority of patients (41, 85.4%) received neoadjuvant therapy, chemoradiotherapy followed by surgery or palliation, as they presented with a more advanced stage of cancer [\[Table 2\]](#).

» Discussion

Esophageal cancer is a malignancy that is relatively common in Sri Lanka and we found that the median overall delay from the appearance of the first symptom to definitive treatment was 13 weeks. Nearly more than half (n = 25, 52.1%) of the patients had an overall delay of more than three months and 12.5% (n = 8) of the patients had a delay exceeding six months. Delay from the appearance of the first symptoms to first contacting the healthcare system (patient delay) accounted for 82.4% of the total, endoscopy delay and delay in histological diagnosis accounted for 7 and 10.7%, respectively.

The median overall delay in the diagnosis in esophageal cancer was 3.25 (3 - 37 weeks) months in which was nearly similar to the median overall delay (3 months) found by some of the previous studies. [Martin et al. \[14\]](#) have found more than four months of median delay from the first symptom

diagnosis of the disease. Both studies were conducted in the UK. However, it is longer than that of the median overall delay (2.2 months) found by Wittzig *et al.*, [15] in Germany, and Wang *et al.* [16] in China. The reasons for these differences are many, some being, the difference in the healthcare systems and different referral patterns. As Sri Lanka is a developing country in South East Asia, in the state sector, we have limited facilities for diagnostic and staging investigations such as Upper GI endoscopy, CT, MRI, and endoscopic ultrasound. Even if available, the state health sector in Sri Lanka being a free health provider, there may be a considerable 'waiting list' for these investigations.










Many studies have indicated a negative relationship between delayed diagnosis and the stage of cancer for lung and colorectal cancer, but there seems to be a controversy regarding the final outcome between diagnostic delay and stage of the disease for esophageal carcinoma. Regarding esophageal carcinoma, some investigators have found that a shorter delay progressively decreases the degree of invasion and increases the survival rate, [17],[18] while others have proven that there is no relationship between delay and the stage of the tumor or mortality. [19],[20],[21] In addition, some have even indicated that shorter delay is associated with poor prognosis. [22] The reason for the contradiction of the studies is not clear. However, the results of the studies by Martin *et al.* and Wang *et al.* [14],[16] in China have suggested that a longer delay before final treatment of esophageal cancer increases the stage of the cancer and thereby worsens the patients' prognosis.

Most patients with esophageal cancer (74%) have dysphagia and some (17%) report odynophagia at the time of diagnosis. [23] Weight loss is also common (57%) and is an independent indicator of poor prognosis if there is a loss of more than 10% body mass. [24] However, in our setting, all the patients presented with dysphagia with or without other symptoms. In our study the majority of the patients (83.3%) had loss of weight when they presented for the endoscopic examination. In addition to the TNM stage, multivariate analyses suggest that a weight loss of more than 10% of body mass, dysphagia, and advanced age are independent predictors of a poor prognosis. [24],[25],[26],[27]

Although esophageal cancer is a common malignancy seen in Sri Lanka (incidence, male = 7.9, female = 9.4), [28] a considerable delay in the diagnosis of this disease still occurs. According to our results it shows that a delay in diagnosis is mainly due to a delay in seeking medical attention (82%). Due to this, the majority of our patients presented at an advanced stage of the disease, which resulted in neoadjuvant therapy prior to surgery or palliative treatment [Table 3] and [Table 4]. Another factor shown in our study is the notable delay in carrying out endoscopy and histology in 18% of the patients. At present Sri Lanka faces an acute shortage of qualified histopathologists in the state sector, and most of the district and provincial hospitals do not have qualified histopathologists. There is also a relative dearth of endoscopists. Therefore, the specimens have to be sent to a central unit in the capital, Colombo, for reporting, and this process may even take several weeks (if not months) to issue a report. In Sri Lanka, carcinoma esophagus is predominantly a disease of the lower socioeconomic strata, and due to financial constraints, 0 these patients are unable to go to the private sector for histopathology services.

The results of our study indicate that long delays in diagnosis and treatment of esophageal cancer still occur in Sri Lanka. This is mainly due to patient delay, although nonavailability of diagnostic facilities also appears to contribute in a notable way. Therefore, a community education program to increase the awareness regarding esophageal cancer may help in reducing patient delay. This will also potentially identify the high risk groups to be screened, and the disease can be identified at an early stage. Therefore a national patient education program with establishment of regional centers of excellence is recommended.

» References

1. Day NE, Varghese C. Oesophageal cancer. *Cancer Survey* 1994;19-20:43-54. 
2. Farin Kamangar, Graña M. Dores, William F. Anderson. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol* 2006;24:2137-50. 
3. Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. *J Postgrad Med* 2003;49:222-8.  [PUBMED]  Full Text
4. Tanaka S, Hirabayashi Y. International comparisons of cumulative risk of oesophagus cancer, from cancer incidence in five continents. *Jpn J Clin Oncol* 2006;36:609-10.  [PUBMED] [FULLTEXT]
5. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. *Int J Cancer* 1999;83:18-29. [Erratum, *Int J Cancer* 1999;83:870-3.] 
6. Muller J, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical treatment of oesophageal carcinoma. *J Surg* 1990;77:845-57. 
7. Enzinger PC, Mayer RJ. Esophageal cancer. *N Engl J Med* 2003;349:2241-52.  [PUBMED] [FULLTEXT]
8. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, *et al.* *AJCC cancer staging ed.* New York: Springer-Verlag; 2002. p. 91-8. 

Impact Factor® for 2011
0.961 (Projected)
® Thomson Reuters

9. Enzinger PC, Ilson DH, Kelson DP. Chemotherapy in esophageal cancer. *Semin Oncol* 1999;26:12-20. [▣](#)
10. Haustermans K, Vanuytsel L, Geboes K, Lerut T, Van Thillo J, Leysen J, *et al.* *In vivo* cell kinetic measurements in human oesophageal cancer: What can be learned from multiple biopsies? *Eur J Cancer* 1994;30A:1787-91. [▣](#) [\[PUBMED\]](#)
11. Schwartz M. A biomathematical approach to clinical tumor growth. *Cancer* 1961;14:1272-94. [▣](#) [\[PUBMED\]](#)
12. Chalasani N, Wo JM, Waring JP. Racial differences in the histology, location, and risk factors of esophageal cancer. *J Clin Gastroenterol* 1998;26:11-3. [▣](#) [\[PUBMED\]](#) [\[FULLTEXT\]](#)
13. Jones RV, Dudgeon TA. Time between presentation and treatment of six common cancers: A study in Devon. *Br J Gen Pract* 1992;42:419-22. [▣](#) [\[PUBMED\]](#) [\[FULLTEXT\]](#)
14. Martin LG, Young S, Sue-Ling H, Johnston D. Delays in the diagnosis of oesophagogastric cancer: A consecutive case series. *Br Med J* 1997;314:467-71. [▣](#)
15. Witzig R, Schönberger B, Fink U, Busch R, Gundel H, Sendler A, *et al.* Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma. *Endoscopy* 2006;38:1122-6. [▣](#)
16. Wang J, Liu F, Gao H, Wei W, Zhang X, Liang Y, *et al.* The symptom-to-treatment delay and stage at the time of treatment in cancer of esophagus. *Jpn J Clin Oncol* 2008;38:87-91. [▣](#) [\[PUBMED\]](#) [\[FULLTEXT\]](#)
17. Robinson E. The fight against the delay in the diagnosis of cancer. *Biomed Pharmacother* 1984;38:321-2. [▣](#) [\[PUBMED\]](#)
18. Christensen ED, Harvard T, Jendresen M, Aggestrup S, Petterson G. The impact of delayed diagnosis of lung cancer on the stage at the time of operation. *Eur J Cardiothorac Surg* 1997;12:880-4. [▣](#)
19. Salomaa ER, Söllinen S, Hiekkänen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. *Chest* 2005;128:2282-8. [▣](#)
20. Holliday HW, Hardcastle JD. Delay in diagnosis of colorectal cancer. *Lancet* 1979;1:1138. [▣](#) [\[PUBMED\]](#)
21. Porta M, Gallen M, Malats N, Planas J. Influence of 'diagnostic delay' upon cancer survival: An analysis of five tumour sites. *J Epidemiol Community Health* 1991;45:225-30. [▣](#)
22. Myrdal G, Lambe M, Hillerdal G, Lamberg K, Agustsson T, Stahle E. Effect of delays on prognosis in patients with non-small cell lung cancer. *Thorax* 2004;59:45-9. [▣](#)
23. Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, *et al.* Esophageal cancer: Results of an American college of surgeons patient care evaluation study. *J Am Coll Surg* 2000;190:562-72. [▣](#) [\[PUBMED\]](#) [\[FULLTEXT\]](#)
24. Fein R, Kelsen DP, Geller N, Bains M, McCormack P, Brennan MF. Adenocarcinoma of the esophagus and gastroesophageal junction: Prognostic factors and results of therapy. *Cancer* 1985;56:2512-8. [▣](#) [\[PUBMED\]](#)
25. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. *J Clin Oncol* 2001;19:305-13. [▣](#) [\[PUBMED\]](#) [\[FULLTEXT\]](#)
26. Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P, Niendorf A, *et al.* Esophageal cancer: The mode of lymphatic tumor cell spread and its prognostic significance. *J Clin Oncol* 2001;19:1970-5. [▣](#) [\[PUBMED\]](#) [\[FULLTEXT\]](#)
27. Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, *et al.* Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastronomy for esophageal carcinoma. *Ann Thorac Surg* 2001;72:1918-25. [▣](#) [\[PUBMED\]](#)
28. Cancer Incidence Data: Sri Lanka. *Cancer Registry*. (6th Publication) 2000. Government Cancer Institute Maharagama. [▣](#)

Figures

[\[Figure 1\]](#)

Tables

[\[Table 1\]](#), [\[Table 2\]](#), [\[Table 3\]](#), [\[Table 4\]](#)


This article has been cited by

- 1 **Face skin neoplasms - Reasons for delayed treatment**
Antoszewski, B., Kasielska, A., Fijałkowska, M.
Polski Przegląd Chirurgiczny/ Polish Journal of Surgery. 2011; 83(7): 361-366
[\[Pubmed\]](#)

Impact Factor® for 2011
0.961 (Projected)
® Thomson Reuters

Cat Gas Generator Sets

Natural and Biogas Fueled. Power Ranges from 100kW to 6M
www.catelectricpowerinfo.com/Gas

AdChoices 

 [Print this article](#)

 [Email this Article to your friend](#)

[Previous article](#)

[Next article](#)

Advertisement



AOS 2012
Asian Oncology Summit
April 13 – 15, 2012 Singapore

Click here to REGISTER online now!
Online registration till 31 March 2012

[Site Map](#) | [What's new](#) | [Copyright and Disclaimer](#)

Online since 1st April '07

© 2007 - 2012 Indian Journal of Cancer | Published by [Medknow](#)

        [View mobile site](#)

ISSN: Print -0019-509X, Online - 1998-4774

Impact Factor® for 2011
0.961 (Projected)
(Thomson Reuters)